ICANS to have no Impact on the Overall Survival in Lymphoma Patients

Release Date: 19-Nov-2020

Researchers have witnessed that the development of immune effector cell-associated neurotoxicity syndrome (ICANS) was not negatively affecting the survival outcomes among relapsed or refractory large B-cell lymphoma patients who are given axicabtagene ciloleucel.  Half of the patients that were enrolled in the respective study received immune effector cell-associated neurotoxicity syndrome after the treatment. The researchers involved in the respective study were majorly focused towards comparing neurotoxicity with others. They reported that neurotoxicity was developing a negative impact on the overall survival of the patients who received CAR-T cell therapy for the treatment of lymphoma.

As per the researchers involved in the respective study, 25 patients experienced ICANS after CAR T-cell infusion. Some of the enrolled patients in the respective study received neurotoxicity had either grade 3 or grade 4 ICANS. Also, ICANS was not observed to affect complete response to the therapy such as progression free survival or overall survival. The analysis of the biomarkers also revealed about the link of the ICANS with the increased levels of fibrinogen as well as lactate dehydrogenase. Therefore, the researchers involved in the respective study concluded through testing it on large group of patient population that neurotoxicity after CAR-T cell therapy has no impact on survival in lymphoma subset.